Yan-ping Lu

Dr. Yan-ping Lu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
HPHong-Ye Peng
Hong-Ye Peng
CLChun-Li Lu
Chun-Li Lu
MZMo Zhao
Mo Zhao
XHXiao-Qiang Huang
Xiao-Qiang Huang
SHShu-Xia Huang
Shu-Xia Huang
WLWenliang LV
Wenliang LV
Our objective was to compare the clinical features of Metabolic dysfunction-associated steatotic liver disease (MASLD) /metabolic alcohol-related liver disease (MetALD)/metabolic associated fatty liver disease (MAFLD)/nonalcoholic fatty liver disease (NAFLD) and the relative risk analysis of metabolic disorders. The National Health and Nutrition Examination Survey for the 2017–2018 cycle was used to screen the participants. Multivariate-adjusted logistic regression models were applied to explore the difference in relative risk analysis between NAFLD/MAFLD/MASLD/MetALD and metabolic disorders. Among the 1,862 eligible individuals, 358(44.84%) had MASLD, 213(11.44%) had MetALD, 841(45.17%) had MAFLD, and 1,125(60.42%) had NAFLD. Positive associations with the risk of hypertension were discovered for MASLD (OR = 2.892, 95%CI = 2.226–3.756), MetALD (OR = 1.802, 95% CI = 1.355–2.398), MAFLD (OR = 3.455, 95%CI = 2.741–4.354) and NAFLD (OR = 1.983, 95%CI = 1.584–2.484). Positive associations with the risk of T2DM were discovered for MASLD (OR = 6.360, 95%CI = 4.440–9.109), MAFLD (OR = 7.026, 95%CI = 4.893–10.090) and NAFLD (OR = 3.372, 95%CI = 2.511–4.528). We discovered similar results for hyperlipidemia. Compared to mild steatosis, moderate to severe steatosis in patients with MASLD (OR = 3.924, 95%CI = 2.399–6.419), MAFLD (OR = 3.814, 95%CI = 2.367–6.144), NAFLD (OR = 4.910, 95%CI = 2.983–8.080) has a higher risk for T2DM. The proposed definitions of MASLD and MetALD are valuable and deserve further exploration. Our findings suggest that MAFLD is a more effective indicator for identifying patients at increased risk for metabolic disorders.

4 August 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
BHBo-Hao Huang
Bo-Hao Huang
BLBo-Han Lv
Bo-Han Lv
DWDong-Jie Wu
Dong-Jie Wu
FXFei-Yang Xiong
Fei-Yang Xiong
YLYan-Bo Li
Yan-Bo Li
WLWenliang LV
Wenliang LV
Background: Liver injury is a multifaceted condition marked by oxidative stress, inflammation, and apoptosis. Schisandra chinensis, a traditional Chinese medicinal herb with a history of use spanning over 2,000 years, exhibits significant hepatoprotective, antioxidant, anti-inflammatory, and anti-apoptotic effects. This study aims to review the therapeutic effects and underlying mechanisms of Schisandra chinensis in mitigating liver injury in animal models.Methods: A systematic review was conducted across eight databases. The methodological quality of the studies was assessed using the Sycle’s RoB tool. Sensitivity and subgroup analyses were performed in cases of high heterogeneity. Publication bias was evaluated using Egger’s test and funnel plots. A meta-analysis was carried out using Stata 18.0.Results: A total of 54 animal studies were included in this review. The results indicated that bioactive compounds in Schisandra chinensis significantly reduced levels of alanine aminotransferase (ALT) [standardized mean difference = −4.74, 95% confidence interval (−5.42, −4.06), p < 0.001, I2 = 90.8%], aspartate aminotransferase (AST) [SMD = −5.10, 95% CI (−5.84, −4.37), p < 0.001, I2 = 91.7%], and alkaline phosphatase (ALP). Additionally, Schisandra chinensis decreased malondialdehyde (MDA) levels while increasing superoxide dismutase (SOD) and glutathione (GSH). Additionally, the results revealed a significant reduction in pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin-1 beta (IL-1β). Subgroup analysis suggested that variations in animal species, drugs, modeling methods, and dosages may contribute to the observed heterogeneity.Conclusion: Schisandra chinensis demonstrates significant therapeutic effects in liver injury, likely due to its anti-inflammatory, antioxidant, and anti-apoptotic properties. However, further research is needed to validate its efficacy and safety.Systematic Review Registration: https://inplasy.com/inplasy-2025-2-0084/, identifier INPLASY202520084.

8 May 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YLYanbo Li
Yanbo Li
ZCZhengmin Cao
Zhengmin Cao
YLYan-ping Lu
Yan-ping Lu
CLChao Lei
Chao Lei
WLWenliang LV
Wenliang LV
Recent insights into the immune response in fibrosis have provided valuable perspectives for the treatment of liver fibrosis. Macrophages, as the most abundant immune cells in the liver, are key drivers of liver fibrosis. They are extensively involved in tissue damage, chronic inflammation, and the progression and regression of liver fibrosis. This study aims to conduct a bibliometric analysis and literature review on the mechanisms by which macrophages contribute to liver fibrosis. Specifically, we analyzed a bibliometric dataset comprising 1,312 papers from 59 countries, 1,872 institutions, and 9,784 authors. Keyword co-occurrence analysis identified key research hotspots, including the role of macrophage subtypes in obesity-related metabolic disorders, the crosstalk between macrophages and hepatic stellate cells through mechanoimmunology, emerging strategies for immune modulation targeting macrophages to promote fibrosis regression and liver regeneration, and new discoveries regarding macrophage crosstalk with other immune cells. In conclusion, this study provides a visual analysis of the current research landscape, hotspots, and trends in the field of macrophages and liver fibrosis, and discusses future directions for further exploration in this area.